Maravai Lifesciences Holdings Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $10.03
- Today's High:
- $10.465
- Open Price:
- $10.44
- 52W Low:
- $9.2
- 52W High:
- $26.55
- Prev. Close:
- $10.42
- Volume:
- 1773397
Company Statistics
- Market Cap.:
- $2.58 billion
- Book Value:
- 3.947
- Revenue TTM:
- $543.92 million
- Operating Margin TTM:
- 39.81%
- Gross Profit TTM:
- $714.04 million
- Profit Margin:
- 13.88%
- Return on Assets TTM:
- 6.1%
- Return on Equity TTM:
- 20.8%
Company Profile
Maravai Lifesciences Holdings Inc had its IPO on 2020-11-20 under the ticker symbol MRVI.
The company operates in the Healthcare sector and Biotechnology industry. Maravai Lifesciences Holdings Inc has a staff strength of 660 employees.
Stock update
Shares of Maravai Lifesciences Holdings Inc opened at $10.44 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $10.03 - $10.47, and closed at $10.3.
This is a -1.15% slip from the previous day's closing price.
A total volume of 1,773,397 shares were traded at the close of the day’s session.
In the last one week, shares of Maravai Lifesciences Holdings Inc have increased by 0%.
Maravai Lifesciences Holdings Inc's Key Ratios
Maravai Lifesciences Holdings Inc has a market cap of $2.58 billion, indicating a price to book ratio of 3.9507 and a price to sales ratio of 4.2247.
In the last 12-months Maravai Lifesciences Holdings Inc’s revenue was $543.92 million with a gross profit of $714.04 million and an EBITDA of $251.37 million. The EBITDA ratio measures Maravai Lifesciences Holdings Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Maravai Lifesciences Holdings Inc’s operating margin was 39.81% while its return on assets stood at 6.1% with a return of equity of 20.8%.
In Q2, Maravai Lifesciences Holdings Inc’s quarterly earnings growth was a negative -32.7% while revenue growth was a negative 71.6%.
Maravai Lifesciences Holdings Inc’s PE and PEG Ratio
- Forward PE
- 30.3951
- Trailing PE
- 18.0263
- PEG
Its diluted EPS in the last 12-months stands at $0.57 per share while it has a forward price to earnings multiple of 30.3951 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Maravai Lifesciences Holdings Inc’s profitability.
Maravai Lifesciences Holdings Inc stock is trading at a EV to sales ratio of 2.103 and a EV to EBITDA ratio of 2.9522. Its price to sales ratio in the trailing 12-months stood at 4.2247.
Maravai Lifesciences Holdings Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $2.26 billion
- Total Liabilities
- $74.92 million
- Operating Cash Flow
- $-24157000.00
- Capital Expenditure
- $25.06 million
- Dividend Payout Ratio
- 0%
Maravai Lifesciences Holdings Inc ended 2024 with $2.26 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $2.26 billion while shareholder equity stood at $520.57 million.
Maravai Lifesciences Holdings Inc ended 2024 with $8.51 million in deferred long-term liabilities, $74.92 million in other current liabilities, 2510000.00 in common stock, $398.16 million in retained earnings and $326.46 million in goodwill. Its cash balance stood at $580.18 million and cash and short-term investments were $580.18 million. The company’s total short-term debt was $12,918,000 while long-term debt stood at $520.34 million.
Maravai Lifesciences Holdings Inc’s total current assets stands at $699.31 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $49.22 million compared to accounts payable of $6.66 million and inventory worth $47.40 million.
In 2024, Maravai Lifesciences Holdings Inc's operating cash flow was $-24157000.00 while its capital expenditure stood at $25.06 million.
Comparatively, Maravai Lifesciences Holdings Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $10.3
- 52-Week High
- $26.55
- 52-Week Low
- $9.2
- Analyst Target Price
- $18.64
Maravai Lifesciences Holdings Inc stock is currently trading at $10.3 per share. It touched a 52-week high of $26.55 and a 52-week low of $26.55. Analysts tracking the stock have a 12-month average target price of $18.64.
Its 50-day moving average was $11.26 and 200-day moving average was $13.28 The short ratio stood at 2.24 indicating a short percent outstanding of 0%.
Around 59.2% of the company’s stock are held by insiders while 9903.5% are held by institutions.
Frequently Asked Questions About Maravai Lifesciences Holdings Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, Viral Clearance Prediction kits, and custom services. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.